Open AccessImpact of interleukin‐28B polymorphism on HCV‐1 infected patients treated with response‐guided therapy
Author(s) -
Chen TsungMing,
Huang PiTeh,
Show BioChia,
Wen ChenFan,
Chen YiPing
Publication year - 2015
Publication title -
advances in digestive medicine
Language(s) - English
Resource type - Journals
ISSN - 2351-9800
DOI - 10.1016/j.aidm.2014.11.001
Subject(s) - medicine , interleukin 28b , ribavirin , odds ratio , gastroenterology , genotype , regimen , confidence interval , single nucleotide polymorphism , hepatitis c virus , sofosbuvir , immunology , biology , virus , biochemistry , gene
Summary Background Single nucleotide polymorphisms (SNPs) of interleukin‐28B (IL28B) were associated with sustained virological response (SVR) in hepatitis C virus genotype 1 (HCV‐1) infected patients treated with a standard 48‐week regimen of peginterferon and ribavirin combination. Whether IL28B SNP genotype would be the influential prognosticator for patients treated with response‐guided therapy (RGT) is still not well understood. Aims To investigate the impact of IL28B rs809917 genotype on HCV‐1 infected patients treated with RGT. Methods A total of 128 consecutive treatment‐naïve HCV‐1 infected patients between July 2006 and July 2011 were analyzed. For rapid virological response (RVR) patients, we allowed an abbreviated 24‐week regimen regardless of baseline viral loads; otherwise, a 48‐week regimen was implemented (for patients with early virological response). The IL28B rs8099917 SNP genotypes were determined accordingly. Results A total of 117 patients (91.4%) were of rs8099917 TT genotype and 11 (8.6%) were of GT/GG genotype. Eighty‐two of the 128 (64.1%) patients achieved SVR, occurring in 54 of 67 RVR patients (80.6%) and 28 of 61 non‐RVR patients (45.9%, p < 0.001). Compared to the GT/GG genotype, patients with the TT genotype had significantly higher SVR rates (67.5% vs. 27.3%; p = 0.008) and low relapse rates (28.2% vs. 70.0%; p = 0.006). The multivariate analysis showed that RVR (odds ratio, 4.51; 95% confidence interval, 1.87–10.90; p = 0.001) and rs8099917 TT genotype (odds ratio, 6.91; 95% confidence interval, 1.53–31.17; p = 0.012) were independent factors associated with SVR. Conclusion For HCV‐1 infected patients who were treated with RGT, the IL28B unfavorable genotype predicted a higher relapse rate; RVR and IL28B favorable genotype were independent factors associated with SVR in patients treated with RGT.